Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2025-07-06 (eleftheriaonline.gr)
Anti-KNOWLEDGE: The untouched
Thymios Georgopoulos writes The Siemens scandal is a case that has been investigating in Greece since 2008 (related to material supply contracts, ...
Read more
2025-06-27 (tradeflock.com)
Patent Wars & Generic Pharma: India's Global Balancing Act
India leads global pharma with affordable generics, facing patent lawsuits & IP pressure. Explore the Novartis case, WTO battles, and health justice.
Read more
2025-06-23 (ieidiseis.gr)
AADE document "unveils" the attempt to spin Lina Nikolopoulou
Court of Justice in the Novartis case and open tax evasion case file.
Read more
2025-06-13 (pagenews.gr)
Samaras for Novartis: "Standing up from a political troupe - their goal is to spin" | NEWS
NEWS - The former prime minister argued that the testimony of "Kelesi" (a nickname of a protected witness) had no evidence and described it as the "biggest cause" of his spit. The reference to Alexis Tsipras and Dimitris Papagelopoulos
Read more
2025-06-06 (mononews.gr)
Eu. Venizelos for Novartis: Ethical perpetrators of the then Prime Minister and Ministers - what he said in trial - .gr
"The moral perpetrators in Novartis's sailor was the then prime minister and ministers": he is the accusation of Evangelos Venizelos in the trial of Novartis.
Read more
2025-06-03 (law360.com)
Novartis Seeks To Block Rival's Generic Blood Pressure Drug -
Novartis has asked a London court to halt a competitor's plans to sell a generic version of its blood pressure medication, arguing that a replica drug will infringe its extended patent protections over the treatment.
Read more
2025-05-14 (law.com)
Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show |
In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment represents roughly five years of disputed royalty payments linked to the drug Jakafi. Quinn Emanuel Urquhart & Sullivan and Paul Hastings represented Wilmington, Delaware-based Incyte.
Read more
2025-05-12 (law360.com)
Novartis Hit With Challenge To Blood Pressure Drug IP -
Generics drugs manufacturer Accord has taken aim at Novartis' protections over a blend of two blood pressure drugs, telling a London court that the combination of both medicines is not inventive.
Read more
2025-04-30 (nzz.ch)
Basel argues on tax money for the pharmaceutical: what the ESC has to do with the most important coordination for years
A campaign near Juso wants to prevent the canton of Basel-Stadt from keeping the pharmaceutical industry happy with subsidies for research. It is about hundreds of millions.
Read more
2025-04-23 (law360.co.uk)
Sandoz, Novartis Cut Price-Fixing Deal With South Carolina
Sandoz, Novartis Cut Price-Fixing Deal With South Carolina
Read more
2025-01-29 (bloomberglaw.com)
Sanofi, Novartis Face Skeptical Judge on Drug Rebate Model Plan
A federal judge appeared doubtful Tuesday about challenges from four drugmakers over a federal health agency's rejection of a discount medicine rebate plan for providers that treat lower-income and uninsured patients.
Read more
2025-01-22 (bloomberglaw.com)
Novartis to Face Mother's Suit Linking Asthma Drug to Autism
Novartis Pharmaceuticals Corp. failed to convince a federal judge to toss a mother's lawsuit alleging it failed to warn people that its asthma drug used off-label to treat preterm labor in pregnant women could cause abnormal brain development in babies.
Read more